

Serial No.: 08/873,601
Filed: June 12, 1997

AMENDMENT

In The Claims:

~~Please cancel Claim 43.~~

~~Please add new Claims 44-57 as follows:~~

44. A cell containing a composition comprising:
(a) an exogenous scaffold comprising at least a first binding site and a second binding site; and
(b) at least a first enzyme and a second enzyme, wherein at least one of said enzymes is heterologous to said cell,
wherein said first enzyme is capable of being bound to said first binding site and said second enzyme is capable of being bound to said second binding site, and wherein said enzymes do not biologically react with said scaffold.

45. A cell containing a composition comprising:
(a) nucleic acid encoding an exogenous scaffold comprising at least a first binding site and a second binding site; and
(b) nucleic acid encoding at least a first enzyme and a second enzyme, wherein at least one of said enzymes is heterologous to said cell,
wherein said first enzyme is capable of being bound to said first binding site and said second enzyme is capable of being bound to said second binding site, and wherein said enzymes do not biologically react with said scaffold..

46. The cell according to Claims 44 or 45, wherein said scaffold comprises at least three binding sites.

47. The cell according to Claims 44 or 45, wherein said scaffold comprises at least four binding sites.

48. The cell according to Claims 1 or 2, wherein said scaffold comprises at least five binding sites.

Serial No.: 08/873,601
Filed: June 12, 1997

49. The cell according to Claims 44 or 45, wherein said binding sites are on the same scaffold molecule.

50. The cell according to Claims 44 or 45, wherein said binding sites are on different scaffold molecules.

51. The cell according to Claims 44 or 45, further comprising:

(c) an exogenous bioactive agent precursor, wherein said agent precursor is from a library of synthetic compounds.

52. The cell according to Claims 44 or 45, wherein said cell is a mammalian cell.

53. The cell according to Claims 44 or 45, wherein said scaffold is linear.

54. The cell according to Claims 44 or 45, wherein said scaffold further comprises a fusion partner.

55. The cell according to Claims 44 or 45, wherein at least one of said enzymes further comprises a fusion partner.

56. The cell according to Claim 54, wherein said fusion partner is a targeting sequence.

57. The cell according to Claim 55, wherein said fusion partner is a targeting sequence.